Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 2/20 | 0.47 |
| ▸ | CTSD | P07339 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 5/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PPID | Q08752 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7309512 | 0.84 | CA12 (0.50) | MEP1BCTSDBACE1CA12CA1 | |
| SCHEMBL30074495 | 0.83 | ITGB3 (0.55) | MEP1BCTSDALDH1A1 | |
| SCHEMBL30074490 | 0.83 | ITGB3 (0.55) | MEP1BCTSDALDH1A1 | |
| SCHEMBL6662122 | 0.81 | KMT2A (0.54) | ALDH1A1ADAM17 | |
| SCHEMBL6662119 | 0.81 | KMT2A (0.54) | ALDH1A1ADAM17 | |
| SCHEMBL4750042 | 0.79 | CTSS (0.61) | BACE1 | |
| SCHEMBL8849130 | 0.79 | ITGA4 (0.52) | ALDH1A1CA12CA1CA7CA14 | |
| SCHEMBL5394016 | 0.78 | CA12 (0.46) | ALDH1A1CA12CA1CA7CA14 | |
| SCHEMBL30074494 | 0.78 | ITGB3 (0.51) | MEP1BCTSDALDH1A1 | |
| SCHEMBL5394620 | 0.78 | SIGMAR1 (0.50) | ALDH1A1CA12CA1CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233886-B1 | COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | OREAL (FR) | 2020-02-26 | — | — | EP | disclosed |
| US-10098827-B2 | Compounds in the family of N-acylamino-amides, compositions comprising them, and uses | L'OREAL (FR) | 2018-10-16 | — | — | US | disclosed |
| US-20170360667-A1 | NEW COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | L'OREAL (FR) | 2017-12-21 | — | — | US | disclosed |
| EP-3233886-A1 | COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | L'Oréal (FR) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096804-A1 | COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | L'OREAL (FR) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360667-A1 | NEW COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | H1-0, CRY1, CCNA1 | MEP1B 2030/4885CTSD 3036/4885ALDH1A1 736/4885 |
| US-10098827-B2 | Compounds in the family of N-acylamino-amides, compositions comprising them, and uses | CRY1, H1-0, C1R | MEP1B 2031/4885CTSD 3245/4885ALDH1A1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.